Show Summary Details
Page of

Risperidone long-acting injection* 

Risperidone long-acting injection*
Chapter:
Risperidone long-acting injection*
Author(s):

Pierre Chue

DOI:
10.1093/med/9780199586042.003.0005
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 17 June 2019

Risperidone is a second-generation (SGA) or atypical (novel) antipsychotic first marketed worldwide in the 1990s as an oral preparation. In 2003, the US Federal Drugs Administration (FDA) approved risperidone long-acting injection (RLAI), the first SGA to be available commercially in an injectable sustained-action formulation (Chue 2003; Ereschefsky & Mascarenas 2003). This chapter describes the development of RLAI, reviews aspects of the pharmacokinetics, summarizes the pivotal trials and clinical data including pharmacoeconomic, and discusses the potential future directions for this novel formulation.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.